Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Venus Medtech (Hangzhou), Inc. Class H ( (HK:2500) ) has issued an update.
Venus Medtech (Hangzhou) Inc. has outlined the terms of reference for its Nomination Committee, a specialized committee under the Board of Directors. The committee, consisting of at least three directors with a majority of independent non-executive directors, is tasked with ensuring diversity and suitable qualifications in board member selection. This initiative is expected to enhance the company’s governance structure and align with its corporate strategy, potentially impacting its industry positioning by promoting a diverse and skilled leadership team.
More about Venus Medtech (Hangzhou), Inc. Class H
Venus Medtech (Hangzhou) Inc. is a joint stock company incorporated in the People’s Republic of China, operating in the medical technology industry. The company focuses on developing and providing innovative medical devices, specifically targeting cardiovascular solutions.
Average Trading Volume: 3,177,973
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$1.16B
Find detailed analytics on 2500 stock on TipRanks’ Stock Analysis page.